Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Heat Shock who wrote (6032)	11/26/1998 5:23:00 AM
From: Rocketman	Respond to of 9719

Well Heat Shock, always good to hear from the lurkers. I'm planning on doing some heat shocking myself tomorrow, to a turkey on the Weber BBQ. If you remember the genital warts days, you certainly have been lurking here for quite a while. Yep, always interested in the 10-100 bagger potential. Good to see someone is researching the usage of Heat Shock Proteins, a very interesting and little understood area of biology. I haven't had a chance to look at much on StressGen yet, AND WOULD LIKE TO HEAR WHAT OTHERS ON THE THREAD THINK. But, the first thing I always want to know is what is their market cap. Since I didn't see it listed anywhere and Yahoo doesn't give a profile, I pulled up the 3Q financials. My first impression from looking at the 3Q numbers is that these guys aren't very good at math: <<<<<< Net loss $ (3,854) $ (1,243) ------------ ------------ ------------ ------------ Weighted average of common shares 25,401 22,643 Loss per common share $0.40 $0.05 >>>>>>>> Let's see, a $3,854,000 loss for the 3Q 98, divided by 25,401,000 shares should yield a loss of $0.1517, not $0.40 But, at least they did the math right for 3Q 97. Now, this press release came out a week ago. You would think that someone would have caught the error and the company would put out a correction. Duhhhh, good to know that Homer Simpson has been able to get a job somewhere doing accounting I guess. At least they error against their favor, so you can't accuse these guys of padding their finances and trying to make things look better than they are. OK, I figured the market cap at 25,401,000 shares out times the quote of $1.60 (is this Canadian or US dollars quoted on Yahoo?) for a market cap of $40,416,000 (Canadian or US??), with $34.3M Canadian dollars in cash. Hmm, not too much research valuation here. I particularly like "the election of Sandra Panem, Ph.D. to the Company's Board of Directors. Dr. Panem is currently the President of Vector Fund Management, the asset management affiliate of Vector Securities International". Seems like they are making the right kind of connections for equity. The alliance with Genzyme Molecular Oncology is also a very good thing. Still they aren't even in clinicals yet, so it is a long way from market, so any short term appreciation has to be hype driven and not really revenue driven. I could see this as a possible 10 bagger sometime during clinical devo, but I think 100 is a big reach. What do the rest of you threadsters think??? Rman

To: Heat Shock who wrote (6032)	11/26/1998 5:46:00 AM
From: Rocketman	Read Replies (1) \| Respond to of 9719

After further thought about Stressgen's math error in their 3Q financials, I'm wondering if that primo BC Bud is as good as what the news reports say it is???? Somebody in the finance departments head ain't tightened up quite right. Another thought, if ENMD with an interesting molecule in mice is worth $300M and Stressgen with an interesting molecule in mice is worth $40M, hmmm, maybe Stressgen needs a better PR agency with better connections to the NY Times. Rick, you ever look at this one? Rman